Phaseline

Companies › DexCom

DexCom: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Metabolic and endocrine; next expected readout Jan 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Insulin Glargine
Insulin receptor agonist
INSRPhase 1Type 2 DiabetesJan 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07681375Insulin GlarginePhase 1Type 2 DiabetesMetabolic and endocrineJan 2027

From the company's SEC filings

Cash of $961m on 2026-09-30; operating cash flow positive

Press releases filed as 8-K in the last year:

Agreements filed with the SEC (item 1.01), last two years

Targets

INSR (1)

Companies with the same targets

Sling Therapeutics Novo Nordisk Gan & Lee Pharmaceuticals. Sanofi Mannkind Gilead Sciences

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.